We are seeking a Series A Investment of $9.0MM to complete the design and development process with our flagship product, secure clearance from the FDA, and commercially launch the Bioptic™ Unit. To date, we have commitments for $2.5M of the round from Level 8 Ventures and UnityPoint Health. Our soft-launch of the product is scheduled for Winter 2021. Pathware’s expenditures during this time will fluctuate between $300k and $500k per month. Future capital will be spent on marketing, sales acceleration, and platform expansion to rapidly saturate both the US and Global markets.

For more information, check out our [Detailed Ask & Use :octicons-triangle-right-24:](./pages/invest/ask_and_use.md)